Summary
The co-administration of antiepileptic drugs (AED) and chemotherapeutic agents in patients with glioblastoma multiforme (GBM) is common. Interactions of chemotherapeutic agents and AED have not been investigated sufficiently. The purpose of this study is to evaluate the effects of enzyme inducing (EI-AED) and non-EI-AED in patients with GBM treated with standard chemotherapeutic agents on survival and haematotoxicity. One hundred and sixty eight glioblastoma patients with standard treatment including surgery, radiotherapy and chemotherapy were retrospectively analysed. Patients were separated into three groups: Group A patients without AED (n=88), Group B patients with EI-AED (n=43), and Group C patients with non-EI-AED (n=37). CCNU was the most frequently used first-line drug in all three groups (Group A: 77%; Group B: 81%; Group C: 78%). Second line treatment, mainly temozolomide, was applicated in 58 of patients and third-line treatment in 9. Carbamazepine was the most frequently administered AED in Group B (81%) and valproic acid in Group C (85%). For statistical analysis, only patients with CCNU first line treatment were calculated. A significant difference regarding survival was detected between Group B (10.8 month) and Group C (13.9 month), as well as increased haematotoxicity for Group C. These results indicate that AED influence the pharmacokinetics of chemotherapeutic drugs in patients with GBM. Valproic acid might be responsible for increasing haematotoxicity. Whether the difference regarding survival between Group B and Group C is due to a decrease of efficacy of chemotherapeutic agents by EI-AED, or due to increased efficacy of chemotherapeutic agents caused by the enzyme inhibiting properties of valproic acid, has to be evaluated in future studies.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
AA Brandes F Vistola U Basso F Berti G Pinna A Rotilio M Gardiman R Scienza S Monfardini M. Ermani (2003) ArticleTitleA prospective study on glioblastoma in the elderly Cancer 1 657–662 Occurrence Handle10.1002/cncr.11097
EL Chang W Yi PK Allen VA Levin RE Sawaya MH. Maor (2003) ArticleTitleHypofractionated radiotherapy for elderly or younger low-performance status glioblastoma patients: outcome and prognostic factors Int J Radiat Oncol Biol Phys 56 519–528 Occurrence Handle10.1016/S0360-3016(02)04522-4 Occurrence Handle12738329
X Durando JJ Lemaire J Tortochaux I Van-Praagh F Kwiatkowski C Vincent C Bailly P Vergelle B Irthum J Chazal JO. Bay (2003) ArticleTitleHigh-dose BCNU followed by autologous hematopoietic stem cell transplantation in supratentorial high-grade malignant gliomas: a retrospective analysis of 114 patients Bone Marrow Transplant 3 559–564 Occurrence Handle10.1038/sj.bmt.1703889
SA Grossman A O’Neil M Grunnet M Mehta JL Pearlman H Wagner M Gilbert HB Newton R. Hellman (2003) ArticleTitleEastern Cooperative Oncology Group. Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394. J Clin Oncol 15 1485–1491 Occurrence Handle10.1200/JCO.2003.10.035
IV Pech K Peterson JG. Cairncross (1998) ArticleTitleChemotherapy for brain tumors Oncology. 12 537–543 Occurrence Handle1:STN:280:DyaK1c3js1Cnsg%3D%3D Occurrence Handle9575527
S Trippoli F Pelagotti A Messori F Vacca M Vaiani S. Maltoni (2003) ArticleTitleSurvival of patients with recurrent malignant glioma treated with temozolomide: a retrospective observational study Drugs R D 4 285–291 Occurrence Handle1:CAS:528:DC%2BD3sXosFChtro%3D Occurrence Handle12952497
R Stupp PY Dietrich S Kraljevic A Pica I Maillard P Maeder R Meuli R Panzer G Pizzolato R Miralbell F Porchet L Regli N Tribolet Particlede RO Mirimanoff S. Leyvraz (2002) ArticleTitlePromising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide J Clin Oncol 1 1375–1382 Occurrence Handle10.1200/JCO.20.5.1375
M Westphal DC Hilt E Bortey P Delavault R Olivares PC Warnke IR Whittle J Jaaskelainen Z. Ram (2003) ArticleTitleA phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma Neuro-oncol 5 79–88 Occurrence Handle1:CAS:528:DC%2BD3sXjtVKltL4%3D Occurrence Handle12672279
PL Moots RJ Maciunas DR Eisert RA Parker K Laporte B. Abou-Khalil (1995) ArticleTitleThe course of seizure disorders in patients with malignant gliomas Arch Neuro 52 717–724 Occurrence Handle1:STN:280:ByqA2cvjsVQ%3D Occurrence Handle7619029
Greenberg HS, Chandler WF, Sandler HM. (1999). Brain Tumors. Contemporary Neurology Series. Oxford University Press. 299–317.
K Lote AE Stenwig K Skullerud H. Hirschberg (1998) ArticleTitlePrevalence and prognostic significance of epilepsy in patients with gliomas Eur J Cancer 34 98–102 Occurrence Handle10.1016/S0959-8049(97)00374-2 Occurrence Handle1:STN:280:DyaK1c3oslejuw%3D%3D Occurrence Handle9624245
S Oberndorfer T Schmal H Lahrmann S Urbanits K Lindner W. Grisold (2002) ArticleTitleThe frequency of seizures in patients with primary brain tumors or cerebral metastasis Wien Klin Wochenschr 30 911–916
PN Patsalos E. Perucca (2003) ArticleTitleClinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs Lancet Neurol 2 347–356 Occurrence Handle10.1016/S1474-4422(03)00409-5 Occurrence Handle1:CAS:528:DC%2BD3sXms1yrtbw%3D Occurrence Handle12849151
PN Patsalos E. Perucca (2003) ArticleTitleClinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs Lancet Neurol 2 473–481 Occurrence Handle10.1016/S1474-4422(03)00483-6 Occurrence Handle1:CAS:528:DC%2BD3sXmslamtbs%3D Occurrence Handle12878435
KT Kivisto HK Kroemer M. Eichelbaum (1995) ArticleTitleThe role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions Br J Clin Pharmacol 40 523–530 Occurrence Handle1:STN:280:BymB2cjgt1E%3D Occurrence Handle8703657
CJ Vecht GL Wagner EB. Wilms (2003) ArticleTitleInteractions between antiepileptic and chemotherapeutic drugs Lancet Neurol 2 404–409 Occurrence Handle10.1016/S1474-4422(03)00435-6 Occurrence Handle1:CAS:528:DC%2BD3sXms1yhsLk%3D Occurrence Handle12849118
MG Neuman NH Shear PM Jacobson-Brown GG Katz HK Neilson IM Malkiewicz RG Cameron F. Abbott (2001) ArticleTitleCYP2E1-mediated modulation of valproic acid-induced hepatocytotoxicity Clin Biochem 34 211–218 Occurrence Handle10.1016/S0009-9120(01)00217-X Occurrence Handle1:CAS:528:DC%2BD3MXltl2hu74%3D Occurrence Handle11408019
PN Patsalos W Froscher F Pisani CM. Rijn Particlevan (2002) ArticleTitleThe importance of drug interactions in epilepsy therapy Epilepsia 43 365–385 Occurrence Handle10.1046/j.1528-1157.2002.13001.x Occurrence Handle1:CAS:528:DC%2BD38XjtlSlur8%3D Occurrence Handle11952767
V Bourg C Lebrun RM Chichmanian P Thomas M. Frenay (2001) ArticleTitleNitroso-urea-cisplatin-based chemotherapy associated with valproate: increase of haematologic toxicity Ann Oncol 12 217–219 Occurrence Handle10.1023/A:1008331708395 Occurrence Handle1:STN:280:DC%2BD3M3gvFantA%3D%3D Occurrence Handle11300327
VA Levin J Stearns A Byrd A Finn RJ. Weinkam (1979) ArticleTitleThe effect of phenobarbital pretreatment on the antitumor activity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl-1-nitrosourea (PCNU), and on the plasma pharmacokinetics and biotransformation of BCNU J Pharmacol Exp Ther 208 1–6 Occurrence Handle1:CAS:528:DyaE1MXhtlarsbk%3D Occurrence Handle759602
PJ Muller CH Tator ML. Bloom (1983) ArticleTitleUse of phenobarbital and high doses of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea in the treatment of brain tumor-bearing mice Cancer Res 43 2068–2071 Occurrence Handle1:CAS:528:DyaL3sXktVShsbs%3D Occurrence Handle6831437
World Health Organization: International Histological Classification of Toumors. Histological Typing of Tumours of the Central Nervous Sysrem. Geneva, WHO, No 2, 1979
JC Buckner JM Reid K Wright SH Kaufmann C Erlichman M Ames S Cha JR O’Fallon LJ Schaaf LL. Miller (2003) ArticleTitleIrinotecan in the treatment of glioma patients: current and future studies on the north central cancer treatment group Cancer 97 2352–2358 Occurrence Handle10.1002/cncr.11304 Occurrence Handle1:CAS:528:DC%2BD3sXjvVSgsrg%3D Occurrence Handle12712456
TF Cloughesy E Filka J Kuhn G Nelson F Kabbinavar H Friedman LL Miller GL. Elfring (2003) ArticleTitleTwo studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen Cancer 97 2381–2386 Occurrence Handle10.1002/cncr.11306 Occurrence Handle1:CAS:528:DC%2BD3sXjvVSgs74%3D Occurrence Handle12712460
MR Fetell SA Grossman JD Fisher B Erlanger E Rowinsky J Stockel S. Piantadosi (1997) ArticleTitlePreirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions New Approaches to Brain Tumor Therapy Central Nervous System Consortium. J Clin Oncol 15 3121–3128 Occurrence Handle1:CAS:528:DyaK2sXmt1Sqtrs%3D Occurrence Handle9294475
HS Friedman WP Petros AH Friedman LJ Schaaf T Kerby J Lawyer M Parry PJ Houghton S Lovell K Rasheed T Cloughsey ES Stewart OM Colvin JM Provenzale RE McLendon DD Bigner I Cokgor M Haglund J Rich D Ashley J Malczyn GL Elfring LL. Miller (1999) ArticleTitleIrinotecan therapy in adults with recurrent or progressive malignant glioma J Clin Oncol 17 1516–1525 Occurrence Handle1:CAS:528:DyaK1MXjsF2ms7o%3D Occurrence Handle10334539
SA Grossman F Hochberg J Fisher TL Chen L Kim R Gregory LB Grochow S. Piantadosi (1998) ArticleTitleIncreased 9-aminocamptothecin dose requirements in patients on anticonvulsants NABTT CNS Consortium. The new approaches to brain tumor therapy. Cancer Chemother Pharmacol 42 118–126 Occurrence Handle10.1007/s002800050794 Occurrence Handle1:CAS:528:DyaK1cXjslWmur0%3D Occurrence Handle9654111
RA. Kramer (1999) ArticleTitleCytochrome P450-inducing antiepileptics increase the clearence of vincristine in patients with brain tumors Clin Pharmocol Ther 66 589–593
JG. Kuhn (2002) ArticleTitleInfluence of anticonvulsants on the metabolism and elimination of irinotecan A North American Brain Tumor Consortium preliminary report. Oncology 16 33–40
E Raymond M Fabbro V Boige O Rixe M Frenay G Vassal S Faivre E Sicari C Germa JM Rodier L Vernillet JP. Armand (2003) ArticleTitleMulticentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naive patients with glioblastoma Ann Oncol 14 603–614 Occurrence Handle1:STN:280:DC%2BD3s7jsVSisw%3D%3D Occurrence Handle12649109
Hildebrand J, Michael Brada (eds). Epileptic seizures. In: Differential Diagnosis in Neuro-oncology. Oxford University Press, 2001, pp 47–58
MJ. Vanden Bent (2003) ArticleTitleThe role of chemotherapy in brain metastases Eur J Cancer 39 2114–2120 Occurrence Handle1:CAS:528:DC%2BD3sXns1KlsLs%3D Occurrence Handle14522368
DF Smith JL Hutton D Sandemann PM Foy MD Shaw IR Williams DW. Chadwick (1991) ArticleTitleThe prognosis of primary intracerebral tumours presenting with epilepsy: the outcome of medical and surgical management J Neurol Neurosurg Psychiatry 54 915–920 Occurrence Handle1:STN:280:By2D2sfpsVQ%3D Occurrence Handle1744647
K Villikka KT Kivisto H Maenpaa H Joensuu PJ. Neuvonen (1999) ArticleTitleCytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors Clin Pharmacol Ther 66 589–593
AE Ahmed M Grissom R El-Azhary A Haque PJ Boor J. Costanzi (1987) ArticleTitleStudies on the mechanism of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU)-induced hepatotoxicity. II. Biochemical and morphological characterization of the injury and its prevention by phenobarbital Cancer Chemother Pharmacol 19 103–108 Occurrence Handle1:CAS:528:DyaL1cXjtFCrtQ%3D%3D Occurrence Handle3105904
PJ McKee J Blacklaw E Butler RA Gillham MJ. Brodie (1992) ArticleTitleVariability and clinical relevance of the interaction between sodium valproate and carbamazepine in epileptic patients Epilepsy Res 11 193–198 Occurrence Handle1:STN:280:ByyD3M%2FptFE%3D Occurrence Handle1396534
E. Perucca (2001) ArticleTitleClinical pharmacology and therapeutic use of the new antiepileptic drugs Fundam Clin Pharmacol 15 405–417 Occurrence Handle1:CAS:528:DC%2BD38Xht1Kqt7w%3D Occurrence Handle11860529
E Perucca S Hebdige GM Frigo G Gatti S Lecchini A. Crema (1980) ArticleTitleInteraction between phenytoin and valproic acid: plasma protein binding and metabolic effects Clin Pharmacol Ther 28 779–789 Occurrence Handle1:CAS:528:DyaL3MXns1Gjuw%3D%3D Occurrence Handle6777108
E Perucca O Dulac S Shorvon T. Tomson (2001) ArticleTitleHarnessing the clinical potential of antiepileptic drug therapy: dosage optimisation CNS Drugs 15 609–621 Occurrence Handle1:CAS:528:DC%2BD3MXntlant70%3D Occurrence Handle11524033
EE Samara RG Granneman GF Witt JH. Cavanaugh (1997) ArticleTitleEffect of valproate on the pharmacokinetics and pharmacodynamics of lorazepam J Clin Pharmacol 37 442–450 Occurrence Handle1:CAS:528:DyaK2sXjs1Cnsbs%3D Occurrence Handle9156377
TK Chang H Chen DJ. Waxman (1994) ArticleTitle1-(2-chloroethyl)-3-cyclohexyl-1-nitrosurea (CCNU modulates rat liver microsomal cyclophosphamide and ifosphamide activation by suppressing cytochrome P450 “C11 messenger RNA levels Drug Metab Dispos 22 673–679 Occurrence Handle1:CAS:528:DyaK2cXmsVGntr0%3D Occurrence Handle7835216
CL. Litterst (1981) ArticleTitleProlonged depression of hepatic microsomal drug metabolism and hemoprotein levels following a single dose of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) Biochem Pharmacol 30 1014–1016 Occurrence Handle1:CAS:528:DyaL3MXkvFSqsbo%3D Occurrence Handle7236311
S Tong Y Hirokata CL Litterst TE. Gram (1984) ArticleTitleInteraction of the oncolytic drug, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea with the mixed-function oxidase system in rats Chem Biol Interact 49 105–119 Occurrence Handle1:CAS:528:DyaL2cXktlaqsL0%3D Occurrence Handle6722931
C Liddle BJ Goodwin J George M Tapner GC. Farrell (1998) ArticleTitleSeparate and interactive regulation of cytochrome P450 3A4 by triiodothyronine, dexamethasone, and growth hormone in cultured hepatocytes J Clin Endocrinol Meta 83 2411–2416 Occurrence Handle1:CAS:528:DyaK1cXksVSisr8%3D
TE. Lackner (1991) ArticleTitleInteraction of dexamethasone with phenytoin Pharmacotherapy 11 344–347 Occurrence Handle1:STN:280:By2D38%2FjsVw%3D Occurrence Handle1923918
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Oberndorfer, S., Piribauer, M., Marosi, C. et al. P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J Neurooncol 72, 255–260 (2005). https://doi.org/10.1007/s11060-004-2338-2
Issue Date:
DOI: https://doi.org/10.1007/s11060-004-2338-2